Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amber Kunkel

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Health Care Management Science|July 26, 2012
Determining minimum staffing levels during snowstorms using an integrated simulation, regression, and reliability modelAmber Kunkel, Laura A McLay
The Lancet. Infectious Diseases|May 24, 2017
Population implications of the use of bedaquiline in people with extensively drug-resistant tuberculosis: are fears of resistance justified?Amber Kunkel, Jennifer Furin, Ted Cohen
Plos Computational Biology|March 25, 2021
Novel anti-malarial drug strategies to prevent artemisinin partner drug resistance: A model-based analysisAmber Kunkel, Michael White, Patrice Piola
Plos Medicine|October 12, 2016
Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based AnalysisAmber Kunkel, Frank G Cobelens, Ted Cohen
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences|April 29, 2015
How could preventive therapy affect the prevalence of drug resistance? Causes and consequencesAmber Kunkel, Caroline Colijn, Marc Lipsitch, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 24, 2025
HIV incidence, migration and diagnosis dynamics, France, 2012-2023: a surveillance and modeling data analysisAmber Kunkel, Amadou Alioum, Florence Lot, et al.
AIDS (London, England)|October 27, 2016
Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemicAmber Kunkel, Forrest W Crawford, James Shepherd, et al.
Antimicrobial Agents and Chemotherapy|May 24, 2017
Antimicrobial Resistance Risks of Cholera Prophylaxis for United Nations PeacekeepersAmber Kunkel, Joseph A Lewnard, Virginia E Pitzer, et al.
Epidemiology and Infection|January 7, 2026
Time series analysis of new HIV diagnoses in France from 2012 to 2022David Kelly, Amber Kunkel, Lauriane Ramalli, et al.
Scientific Reports|June 15, 2021
The urgency of resuming disrupted dog rabies vaccination campaigns: a modeling and cost-effectiveness analysisAmber Kunkel, Seonghye Jeon, Haim C Joseph, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Health Care Management Science|July 26, 2012
Determining minimum staffing levels during snowstorms using an integrated simulation, regression, and reliability modelAmber Kunkel, Laura A McLay
The Lancet. Infectious Diseases|May 24, 2017
Population implications of the use of bedaquiline in people with extensively drug-resistant tuberculosis: are fears of resistance justified?Amber Kunkel, Jennifer Furin, Ted Cohen
Plos Computational Biology|March 25, 2021
Novel anti-malarial drug strategies to prevent artemisinin partner drug resistance: A model-based analysisAmber Kunkel, Michael White, Patrice Piola
Plos Medicine|October 12, 2016
Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based AnalysisAmber Kunkel, Frank G Cobelens, Ted Cohen
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences|April 29, 2015
How could preventive therapy affect the prevalence of drug resistance? Causes and consequencesAmber Kunkel, Caroline Colijn, Marc Lipsitch, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 24, 2025
HIV incidence, migration and diagnosis dynamics, France, 2012-2023: a surveillance and modeling data analysisAmber Kunkel, Amadou Alioum, Florence Lot, et al.
AIDS (London, England)|October 27, 2016
Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemicAmber Kunkel, Forrest W Crawford, James Shepherd, et al.
Antimicrobial Agents and Chemotherapy|May 24, 2017
Antimicrobial Resistance Risks of Cholera Prophylaxis for United Nations PeacekeepersAmber Kunkel, Joseph A Lewnard, Virginia E Pitzer, et al.
Epidemiology and Infection|January 7, 2026
Time series analysis of new HIV diagnoses in France from 2012 to 2022David Kelly, Amber Kunkel, Lauriane Ramalli, et al.
Scientific Reports|June 15, 2021
The urgency of resuming disrupted dog rabies vaccination campaigns: a modeling and cost-effectiveness analysisAmber Kunkel, Seonghye Jeon, Haim C Joseph, et al.
Pageof 3